Investigating how glucocorticoids and immune cells help recover lung function after injury.
Official title: The effect of endogenous and exogenous glucocorticoids acting through regulatory T cells on resolution of ALI and the contribution of host genetic variability.
Funded at Univ of North Carolina Chapel Hill · NIH-11050204 · Data updated 2026-11-12
This study is looking at how special immune cells help heal the lungs after serious conditions like ARDS and pneumonia, and it will see how a common steroid medication affects these cells to find out why some people recover better than others, with the hope of creating more tailored treatments for lung injuries.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project start | February 1, 2025 |
| Project end | November 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $775,992 |
| NIH project number | 1R01HL173765-01A1 |
| Project ID | NIH-11050204 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include adults diagnosed with acute respiratory distress syndrome (ARDS) or pneumonia.
✕Less likely to help
Patients with chronic lung diseases or those who do not have acute lung injuries may not benefit from this research.
What this research studies
This research focuses on understanding how certain immune cells, known as regulatory T cells, contribute to the healing process of the lungs following acute respiratory distress syndrome (ARDS) and pneumonia. The study will explore the effects of glucocorticoids, a type of steroid medication, on these immune cells and how they may influence recovery. By examining the genetic variability among patients, the research aims to identify why some individuals respond better to glucocorticoid treatment than others. This could lead to more personalized and effective therapies for patients suffering from lung injuries.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for patients with acute lung injuries, enhancing their recovery and overall lung function.
How similar studies have gone: Previous research has shown promising results in understanding the role of immune cells in lung recovery, but this specific approach to glucocorticoid effects on Tregs is relatively novel.
Where this research is happening
-
Univ of North Carolina Chapel Hill
Chapel Hill, United States Active
Researchers
- Principal investigator: Mock, Jason Robert — Univ of North Carolina Chapel Hill
- Study coordinator: Mock, Jason Robert
Related research
Other NIH-funded projects on the same topics.
-
A center for coordinating data related to heart and blood health.
This study is working on a new system to gather and analyze health information about heart and blood disorders, which could lead to better ways to diagnose and treat these conditions, ultimately helping patients like you.
-
Healthy work design and worker well-being
A multi-site program aims to improve the health and well-being of workers by studying how work design affects safety, stress, and quality of life.
-
Unified and fair multimodal learning for autoimmune diseases
A patient-friendly AI approach will combine many kinds of health data to improve diagnosis and personalized care for autoimmune diseases, including lupus.
-
Structural factors linking minimum wage, COVID-19, and community violence
A long-term study will explore whether higher minimum wages and pandemic-related economic factors are connected to changes in violence in US communities.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
How HPV interacts with our cells' DNA damage system and its effect on cancer
This project looks at how high-risk HPV uses the body’s DNA repair machinery to replicate and potentially drive cancer, with the goal of finding new antiviral and cancer-fighting approaches for people affected by HPV-related diseases.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.